scholarly journals Transdermal therapeutic system of carvedilol: Effect of hydrophilic and hydrophobic matrix on in vitro and in vivo characteristics

2007 ◽  
Vol 8 (1) ◽  
pp. E13-E20 ◽  
Author(s):  
Udhumansha Ubaidulla ◽  
Molugu V. S. Reddy ◽  
Kumaresan Ruckmani ◽  
Farhan J. Ahmad ◽  
Roop K. Khar
Keyword(s):  
Therapeutic System ◽  
Transdermal Therapeutic System ◽  
Hydrophobic Matrix

Transdermal therapeutic system of isradipine: Effect of hydrophilic and hydrophobic matrix on In Vitro and Ex vivo characteristics

2010 ◽  
Vol 33 (7) ◽  
pp. 1025-1033 ◽  
Author(s):  
Mamatha Tirunagari ◽  
Venkateswara Rao Jangala ◽  
Mukkanti Khagga ◽  
Ramesh Gannu
Keyword(s):  
Ex Vivo ◽  
Therapeutic System ◽  
Transdermal Therapeutic System ◽  
Hydrophobic Matrix

A New Transmucosal Therapeutic System: Overview of Formulation Development and in Vitro/in Vivo Clinical Performance

1993 ◽  
Vol 19 (14) ◽  
pp. 1755-1808 ◽  
Author(s):  
Y. Nozaki ◽  
M. Kakumoto ◽  
M. Ohta ◽  
K. Yukimatsu ◽  
Yie W. Chien
Keyword(s):  
Clinical Performance ◽  
Therapeutic System ◽  
Formulation Development

Controlled In Vivo Release of Nicorandil from a Carvone-Based Transdermal Therapeutic System in Human Volunteers

Drug Delivery ◽  
2006 ◽  
Vol 13 (1) ◽  
pp. 69-77 ◽  
Author(s):  
Y. S. R. Krishnaiah ◽  
S. M. Al-Saidan ◽  
D. V. Chandrasekhar ◽  
V. Satyanarayana
Keyword(s):  
Therapeutic System ◽  
Transdermal Therapeutic System ◽  
In Vivo Release ◽  
Human Volunteers

scholarly journals MICRONEEDLES AS A WAY TO INCREASE THE TRANSDERMAL INSULIN DELIVERY

2017 ◽  
Vol 18 (4) ◽  
pp. 87-92
Author(s):  
E. G. Kuznetsova ◽  
V. A. Ryzhikova ◽  
L. A. Salomatina ◽  
V. A. Tukmachev ◽  
V. I. Sevastianov
Keyword(s):  
Absorption Spectrum ◽  
Insulin Release ◽  
Genetically Engineered ◽  
Therapeutic System ◽  
Insulin Absorption ◽  
Rabbit Skin ◽  
Transdermal Therapeutic System ◽  
Franz Diffusion Cells ◽  
Native Skin

Aim: to prove the possibility of increasing the diffusion of insulin through the skin in vitro with pre-applying microneedles.Materials and methods. Microemulsion for transdermal therapeutic system of insulin has been used in vitro studies. Genetically engineered human insulin has been used in this research. Applicators with silicon microneedles (40 and 150 microns long) have been used to enhance the diffusion fl ux of drug substance. The dynamics of insulin release from the transdermal therapeutic systems through the rabbit skin has been studied in glass Franz diffusion cells in analyzer diffusion of drugs HDT 1000 (Copley Scientifi c Ltd., UK). Insulin has been labeled with fl uorescein isothiocyanate to separate the insulin absorption spectrum from the spectra of native skin proteins at spectrophotometer measurements.Results. The amounts of insulin delivered through the skin in vitro after previous application of microneedles of 40 and 150 microns are 282.5 ± 61.1 and 372.3 ± 7.0 microgram, respectively. This is 1.4 and 1.9 times more than in the transdermal system without microneedles.Conclusion.The conditions for increasing the diffusion of insulin through the skin in a model transdermal therapeutic system with microneedles (length – 150 microns, duration of pre-application – 1 hour) have been found.

scholarly journals Comparative analysis of pharmacokinetic parameters of transdermal and intramuscular administration of Galavit®

2021 ◽  
Vol 23 (2) ◽  
pp. 114-121
Author(s):  
E. G. Kuznetsova ◽  
O. M. Kuryleva ◽  
L. A. Salomatina ◽  
S. V. Kursakov ◽  
Z. Z. Gonikova ◽  
...  
Keyword(s):  
Dosage Form ◽  
Animal Experiments ◽  
The Body ◽  
Intramuscular Administration ◽  
Pharmacokinetic Parameters ◽  
Therapeutic System ◽  
Transdermal Administration ◽  
Maximum Serum ◽  
Transdermal Therapeutic System

Introduction. Immunomodulator Galavit® is a promising domestic drug for the prevention and treatment of various infectious diseases. Earlier, the authors have developed and investigated in vitro its new dosage form – transdermal therapeutic system (TTS). Positive results from experiments made it possible to proceed to the study of the pharmacokinetic parameters of Galavit® TTS in animals.Objective: to compare the pharmacokinetic parameters of intramuscular and transdermal administration of immunomodulator Galavit® in animal experiments.Materials and methods. Sodium aminodihydrophthalazinedione was used as a substance in the form of a powder to prepare a solution for intramuscular administration of 100 mg (trade name Galavit®, manufacturer SELVIM LLC). The pharmacokinetics of transdermal and intramuscular injections were studied in male Chinchilla rabbits weighing 4.5–5.0 kg. Serum sodium aminodihydrophthalazinedione concentrations in animals were determined by highperformance liquid chromatography using a specially developed technique.Results. In contrast to the injection method, a prolonged and uniform inflow of the drug substance (MP) into the body is observed for percutaneous administration of sodium aminodihydrophthalazinedione. The maximum serum Galavit® concentration for a 40 mg dose (0.172 ± 0.054 μg/mL) and for a 80 mg dose (1.16 ± 0.22 μg/mL) remained at a constant level for 9 and 8 hours, respectively. The relative bioavailability of the Galavit® transdermal therapeutic system was 0.65 and 1.06 for the same doses.Conclusion. Application of Galavit® 80 mg transdermal therapeutic system provides bioavailability that is similar to the intramuscular administration of this drug at the same dose. At the same time, its maximum serum concentration significantly decreases and the retention time of Galavit® in the body increases by more than 10 times, which can contribute to prolongation of the drug effect. Due to the current growing interest in the use of immunomodulator Galavit® for coronavirus infection COVID-19, the development and study of a new dosage form is a promising task

Sign in / Sign up

Export Citation Format

Share Document